UNSPSC 51392227: Tizanidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H8ClN5S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B53E3NMY5C, chemically known as 2,1,3-benzothiadiazol-4-amine, 5-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-, monohydrochloride but more generally known as tizanidine hydrochloride, which bears US NIH Compound Identifier 114869. European Medicines Agency schedules Tizanidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04895MIG.

UNSPSC 51392227 Tizanidine hydrochloride is a Commodity code nominally describing a specific muscle relaxant pharmaceutical, but recent state and local procurement activity shows little alignment with this narrowly defined product. The two recent opportunities tagged under this code address distinctly different pharmaceutical and health-system needs: Seminole County's procurement of naloxone and drug deactivation systems for community health support, and the Texas Health and Human Services Commission's exploratory RFI on direct-to-manufacturer prescription programs. Neither solicitation targets tizanidine hydrochloride or muscle relaxants specifically. The code appears to be a catch-all or mislabeling artifact in state procurement systems rather than a reliable category for vendors focused on this active pharmaceutical ingredient. Issuing bodies using the code span county-level health departments and state health agencies, but the small sample size and the apparent taxonomy mismatch limit confidence in characterizing an established buyer base.

Geographic activity centers on Florida and Texas based on the two recent postings, though the narrow opportunity sample provides insufficient basis to project broader state or regional concentration. Seminole County's IFB for naloxone and drug deactivation systems, posted June 30, 2026, with a due date of July 26, 2023, seeks 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract will carry a two-year initial term with one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, with the same due date, is a preliminary market-intelligence solicitation exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements, with no award value or formal evaluation criteria specified at this stage. The code shows minimal recent relevant activity; vendors should verify actual code assignment before allocating resources to pursue opportunities tagged under it.